TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06295848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: An individual program will be organized for each patient according to the exercise test result. Since the patients have both arthritis and HTN, aerobic exercises will be given at moderate intensity (40-60% VO2 reserve) according to ACMS recommendations. Xrcise Runner Med treadmill and Xrcise Care 2.5.8.3 software will be used for aerobic exercises. Resistant exercises will be given under the supervision of a physiotherapist, calculating 1 repetitation maximum (1-RM) in the main muscle groups.Patients will perform isotonic exercises with 3 sets of 15 repetitions with a resistance of 60% of 1-RM. The education sessions will be conducted by a multidisciplinary team of health professionals (nurse, physiotherapist and dietician) under the leadership of a clinician experienced in CR. Education topics will consist of 60-minute sessions covering heart-healthy eating, setting health-related goal, exercise, diet, healthy weight loss, smoking cessation, and stress/coping.
Study: NCT04141358

Intervention type: DIAGNOSTIC_TEST
Intervention: Advanced ultrasound measurements
Description: Clinical interventions and procedures:~* Consent at 0 week~* Clinical data collection at 0 week~* Strain for native artery at 0 week~* Young's modulus for native artery at 0 week~* Intimal medial thickness for native artery at 0 week~* Ultrasound blood volume flow measurement at 0 week~* Vessel diameter at 0 week~* Blood pressure at 0 week~* BMI at 0 week~* Intra-operative blood volume flow measurement at AVF surgery time~* Strain for native artery at 6 weeks~* Young's modulus native artery at 6 weeks~* Intimal medial thickness native artery arteries at 6 weeks~* Ultrasound blood volume flow measurement at 6 weeks~* Vessel diameter at 6 weeks~* Blood pressure at 6 weeks~* BMI at 6 weeks
Study: NCT06386926

Intervention type: OTHER
Group type: OTHER
Intervention: Electro Therapy
Description: radial shockwave 3 sessions one session per week for four consecutive weeks ,receive Ultrasound phonophoresis using diclofenac Na+ 12 session, 3 sessions per week and conventional physical therapy modalities in the form of 3 sessions every week for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro Therapy
Description: radial shockwave 3 sessions one session per week for four consecutive weeks ,receive Ultrasound phonophoresis using diclofenac Na+ 12 session, 3 sessions per week and conventional physical therapy modalities in the form of 3 sessions every week for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro Therapy
Description: radial shockwave 3 sessions one session per week for four consecutive weeks ,receive Ultrasound phonophoresis using diclofenac Na+ 12 session, 3 sessions per week and conventional physical therapy modalities in the form of 3 sessions every week for 8 weeks
Study: NCT06241716

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted localization, US-AS
Description: In the US-AS group, ultrasonic prescan to determine the best intervertebral space, best puncture Angle and best puncture depth. The optimal puncture section considered by the operator was selected to record the best gap, puncture Angle and depth.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-assisted localization, US-AS
Description: In the US-AS group, ultrasonic prescan to determine the best intervertebral space, best puncture Angle and best puncture depth. The optimal puncture section considered by the operator was selected to record the best gap, puncture Angle and depth.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound guidance, US-RTG
Description: In the US-RTG group, the optimal puncture section considered by the operator was selected and recorded directly in the plane of the paracentral transverse section, out of the plane of the paracentral sagittal section or in the plane of the paracentral sagittal section for real-time ultrasound guided lumbar epidural anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Real-time ultrasound guidance, US-RTG
Description: In the US-RTG group, the optimal puncture section considered by the operator was selected and recorded directly in the plane of the paracentral transverse section, out of the plane of the paracentral sagittal section or in the plane of the paracentral sagittal section for real-time ultrasound guided lumbar epidural anesthesia.
Study: NCT05758766

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant-based omega-3-FA
Description: Plant-based omega 3 Fatty Acids
Study: NCT05747716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBRT, Fruquintinib, Cadonilimab
Description: Radiation: Stereotactic body radiationtherapy (SBRT) for metastatic sites (less than 5) Fruquintinib: 5mg, po, everyday; Cadonilimab: 10mg/kg, iv, q3w
Study: NCT05453448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir alafenamide
Description: Antiviral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: entecavir
Study: NCT04948814

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: FMT utilizing stool from healthy children

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: 40mg/kg/day
Study: NCT05369507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Care Coordination
Description: Participants randomly assigned to the virtual care coordination group will use a mobile app to assist in HCV treatment care coordination.
Study: NCT05282875

Intervention type: DRUG
Intervention: management of immunosuppressive therapy
Description: 3 groups :~* Discontinuation of immunosuppressive agents~* Reduction of immunosuppressive agents~* Maintenance of immunosuppressive agents
Study: NCT05794880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)
Description: Participants in this study will receive a blood stem cell transplant, which will use an investigational device called the CliniMACs device to remove alpha/beta T cells and B cells from the blood cells collected from the donor. This is called T cell depletion and B cell depletion.
Study: NCT04712123

Intervention type: OTHER
Intervention: relapse due to S. aureus
Description: to find out if it is the same S. aureus in both infections
Study: NCT05130684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: adding nivolumab to conventional neoadjuvant CRT
Study: NCT04815681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common Elements Toolbox
Description: COMET is an online unguided self-help intervention that lasts approximately 40-50 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: The active control condition includes an online self-awareness program that lasts approximately 40-50 minutes. Participants in the control condition will receive access to the intervention after data collection for the study has been completed.
Study: NCT05493475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fentanyl Test Strips
Description: A brief fentanyl test strip (FTS) education intervention will be given to participants at court sites in the intervention arm after enrollment and collecting baseline data. It will be offered one-on-one with participants and will include the purpose, benefits, and limitations of FTS testing, and information on how to use FTS, interpret the results, what to do if the FTS is positive, and how to use FTS for different drug delivery methods. Participants will practice and demonstrate use of the FTS, and the short video on how to interpret the FTS will include an on-camera statement on the importance of testing for fentanyl. The video will be accessible to participants after study enrollment. Participants will be advised of the possibility of both false positive/negative results, and that the drugs may be mixed with other substances not detectable with FTS. Participants will be encouraged to practice other harm reduction strategies.
Study: NCT05683964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]
Description: per standard care

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
Description: Per standard care
Study: NCT05996783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colli-Pee Small Volumes
Description: Women will self-collect a first-void urine sample at home upon receipt of the study package using the Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube is prefilled with a preservative (UCM, Novosanis, Belgium). Women will send the collector vial containing first-void urine along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colli-Pee Small Volumes
Description: Women will self-collect a first-void urine sample at home upon receipt of the study package using the Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube is prefilled with a preservative (UCM, Novosanis, Belgium). Women will send the collector vial containing first-void urine along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
Study: NCT05694767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM313 Injection
Description: intravenous CM313 administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with CD38 monoclonal antibody (CM 313: 16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg CM313 once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of CM313 after treatment.
Study: NCT05996783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evalyn Brush
Description: Women will self-collect a vaginal sample at home upon receipt of the study package using the Evalyn Brush device (Rovers Medical Devices, The Netherlands). Women will send the used brush along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evalyn Brush
Description: Women will self-collect a vaginal sample at home upon receipt of the study package using the Evalyn Brush device (Rovers Medical Devices, The Netherlands). Women will send the used brush along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
Study: NCT05453006

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COPAN 552c.80 FLOQSwab
Description: The study will implement HPV self-sampling as an option for cervical cancer screening alongside usual care for Somali women, and evaluate changes pre and post implementation, compared to Fairview intervention clinics.
Study: NCT04784754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin capsules will be prepared using hypromellose capsules containing 3 mg or 30 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.
Study: NCT05124314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone, Oral, 200 Mg
Description: Adding 600 mg of oral Mifepristone to the regular treatment with vaginal Misoprostol 800 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol Pill
Description: Regular treatment with vaginal Misoprostol 800 mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol Pill
Description: Regular treatment with vaginal Misoprostol 800 mcg
Study: NCT05528185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct participation of the family member in the daily rounds
Description: When the team arrives at the participating family member's room, the family member will be invited by a member of the healthcare team to come out of the room. The rounding team and structure will be the same as the usual care group with the following exceptions: (1) the family member will be invited to participate in the rounds outside their relative's room; (2) the family member will be provided with an orientation to the medical team members; (3) the family member will be allowed to engage and participate throughout the rounds; (4) at the end of the rounds, the team will summarize the patient's daily care plan; (5) the family member will be prompted to ask questions.
Study: NCT05801874

Intervention type: DIAGNOSTIC_TEST
Intervention: Movement analysis
Description: Qualitative and quantitative computerized and instrumental assessment of gait and posture.

Intervention type: DIAGNOSTIC_TEST
Intervention: Movement analysis
Description: Qualitative and quantitative computerized and instrumental assessment of gait and posture.
Study: NCT04784754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin capsules will be prepared using hypromellose capsules containing 3 mg or 30 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be prepared using hypromellose capsules, filled using microcrystalline cellulose. This is the same excipient used in the preparation of the interventional drug. Placebo will be administered orally three times a day for 14 days in the same regimen used for the intervention.
Study: NCT05575544

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture plus morphine
Description: The acupuncture was combined with intravenous use of morphine to achieve anesthesia during the ablation procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture plus morphine
Description: The acupuncture was combined with intravenous use of morphine to achieve anesthesia during the ablation procedure
Study: NCT05196373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: STP705 Powder for Injection composed of siRNA-TGF-B1 and siRNA-COX-2 packged in a proprietary polymer nanoparticle formulation for delivery.
Study: NCT06306326

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3dMD technology
Description: By taking photos using 3dMD, we obtained preoperative, immediate postoperative, and long-term postoperative three-dimensional data of patients. The software automatically fused the data to obtain the volume difference of facial volume at different time points, and then divided it to obtain the objective data of facial volume improvement rate. To improve the reliability of the measurements, two researchers measured independently and took the average value.
Study: NCT06580470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Cognitive Behavioral Therapy for Menopause
Description: Cognitive Behavioral Therapy for Menopause (CBT-Meno) is an evidenced-based intervention that includes psychoeducation, cognitive, and behavioral strategies for coping with common menopause symptoms and experiences. In Aims 1 and 2, CBT-Meno materials and procedures will be tailored for women Veterans through an iterative process involving: a) data from preliminary studies and a pre-pilot trial; b) input from content area experts; and c) stakeholder advisory panels. This tailored version of CBT-Meno will then be test in this clinical trial.
Study: NCT05196373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: STP705 Powder for Injection composed of siRNA-TGF-B1 and siRNA-COX-2 packged in a proprietary polymer nanoparticle formulation for delivery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: STP705 Powder for Injection composed of siRNA-TGF-B1 and siRNA-COX-2 packged in a proprietary polymer nanoparticle formulation for delivery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: STP705 Powder for Injection composed of siRNA-TGF-B1 and siRNA-COX-2 packged in a proprietary polymer nanoparticle formulation for delivery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: STP705 Powder for Injection composed of siRNA-TGF-B1 and siRNA-COX-2 packged in a proprietary polymer nanoparticle formulation for delivery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: STP705 Powder for Injection composed of siRNA-TGF-B1 and siRNA-COX-2 packged in a proprietary polymer nanoparticle formulation for delivery.
Study: NCT06360471

Intervention type: OTHER
Intervention: fertility preservation
Description: If a patient have a desire to fertility preservation, oocyte freezing or embryo freezing will be offered.
Study: NCT04783870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg PO QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06508177

Intervention type: OTHER
Intervention: İnterfascial plane block
Description: Interfascial plane blocks will be added to the routine analgesia plan as part of multimodal analgesia.

Intervention type: OTHER
Intervention: Standart analgesia plan
Description: This is the routine analgesia plan applied in our clinic.

Intervention type: OTHER
Intervention: Standart analgesia plan
Description: This is the routine analgesia plan applied in our clinic.
Study: NCT05706961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power Walking
Description: For 1- 2 Week 60% of the target heart rate with 5,000 to 7,500 steps/day Total 30 min Session The exercise intensity was set at 60% of the target heart rate during the first 2 weeks.~For 3- 4 week 70 % of the target heart rate with 7,500 to 10,000 steps/day Total 30 min Session B) Progressive increase walk according to 6MWD as improved Low intensity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Outpatient Cardiac Rehabilitation
Description: For 1- 2 week Standardized Outpatient Cardiac Rehabilitation (includes warm up of 5 min, aerobic 60 % of of target heart rate, resistive ex with 1- 3 kg of weight for 20 min and 10 min of cool down)~For 3 - 4 week Standardized Outpatient Cardiac Rehabilitation (includes warm up of 5 min, aerobic 70 % of target heart rate, resistive ex with 2- 3 kg of weight for 20 min and 10 min of cool down)
Study: NCT04751968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Intervention
Description: The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. Adolescents are taught skills for coping and relating more effectively with others. Caregivers learn about adolescent development, effective parenting and the importance of connection. The groups consist of 6 stand-alone modules permitting rolling entry and prompt access. Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, homework from that week's intervention group and crisis resources.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced Treatment as Usual
Description: Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, a mental health tip and crisis resources.
Study: NCT05198531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2858 Injection
Description: TQB2858 Injection, a bifunctional fusion protein against Programmed death ligand 1 (PD-LI) and transforming growth factor-β (TGF-β). TQB2858 Injection blocks the PD-1/PD-L1 pathway and neutralizes TGF-β in the tumor microenvironment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsule
Description: Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine hydrochloride injection
Description: Gemcitabine hydrochloride, cell cycle-specific antimetabolites, mainly acting on tumor cells in the DNA synthesis phase (S phase cell). Under certain conditions, it can prevent the progression from G1 phase to S phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Injection
Description: After cisplatin enters cells, it reacts with DNA to form cross-links between two points or two strands in DNA, thereby inhibiting DNA replication and transcription, resulting in DNA breaks and miscoding.
Study: NCT06076772

Intervention type: DRUG
Intervention: Palbociclib
Description: The investigator will follow the patients after starting treatment to follow and observe the outcome of the treatment side effects and risk factors

Intervention type: DRUG
Intervention: Palbociclib
Description: The investigator will follow the patients after starting treatment to follow and observe the outcome of the treatment side effects and risk factors
Study: NCT06263660

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Keto-like supplement
Description: Participants will consume 9.25g stick packs of the keto-like supplement dissolved in water 3 times per day for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume 9.25g stick packs of placebo dissolved in water 3 times per day for 8 weeks.
Study: NCT04841694

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Bacillus indicus
Study: NCT06044129

Intervention type: DEVICE
Intervention: Mri scan of fetal head and pelvis
Description: The pelvic parameters and fetal head parameters of pregnant women were measured by MRI, including pelvic entrance plane, middle pelvic plane, pelvic outlet plane, pubic arch Angle, double parietal diameter, occipitofrontal diameter, and suboccipital fontanel diameter.
Study: NCT06236308

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTAX03 10mg
Description: TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic techniques followed by terminal sterilization by gamma-irradiation in compliance with Current Good Tissue Practices (CGTP) and Current Good Manufacturing Practices (CGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTAX03 25mg
Description: TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic techniques followed by terminal sterilization by gamma-irradiation in compliance with Current Good Tissue Practices (CGTP) and Current Good Manufacturing Practices (CGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Control Saline
Description: 2 mL Sterile, preservative free 0.9% NaCl